Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Novel Anti-Cancer Therapeutics and Therapies

Investigational New Drugs OnlineFirst articles

23.02.2018 | PHASE II STUDIES

A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)

Background The inhibition of insulin-like growth factor receptor-1 (IGF-1R) induces cell cycle arrest and enhancing the effect of castration by delay of progression of human prostate cancer models. Linsitinib is a small molecule and potent dual …

20.02.2018 | PRECLINICAL STUDIES Open Access

The concomitant use of lapatinib and paracetamol - the risk of interaction

Lapatinib is a tyrosine kinase inhibitor used for the treatment of breast cancer. Paracetamol is an analgesic commonly applied to patients with mild or moderate pain and fever. Cancer patients are polymedicated, which involves high risk of drug …

20.02.2018 | SHORT REPORT

Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report

Introduction Tumor lysis syndrome (TLS) is a life-threatening emergency caused by rapid cell death as a result of anti-tumor therapy. In the era of targeted therapy it has increasingly been observed in solid malignancies such as hepatocellular …

19.02.2018 | PRECLINICAL STUDIES

Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells

Purpose The combretastatins (CAs) are known to exhibit anti-tumour activity but the underlying mechanism remains to be fully elucidated. Inflammation plays a critical role in altering the function of cancer cells and evasion of cell death and …

17.02.2018 | PHASE I STUDIES

A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors

Background This phase I dose-escalation study investigated the safety of the Smoothened inhibitor taladegib in Japanese patients with advanced solid tumors. Methods Patients received taladegib orally once daily for 28-day cycles, using a 3 + 3 …

Aktuelle Ausgaben

Weitere Informationen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise